The future presents significant challenges and opportunities for Medicaid directors, who can leverage their purchasing power to influence improvements in health care quality, delivery and value.
Six Medicaid directors have been chosen to participate as fellows in the 2011 class of the Medicaid Leadership Institute. The Robert Wood Johnson Foundation (RWJF) supports this initiative to enhance the leadership capacity of Medicaid directors so their programs can serve as national models for high-quality, cost-effective care.
According to the Center for Health Care Strategies (CHCS), by 2014, Medicaid will become the largest healthcare purchaser in the nation, with the addition of 16 million to 20 million new beneficiaries. That will present significant challenges and opportunities for Medicaid directors, who can leverage their purchasing power to influence improvements in healthcare quality, delivery and value.
“Each Medicaid director is essentially the CEO of one of the largest health insurance companies in his or her state,” says Melanie Bella, senior vice president at CHCS and director of the Medicaid Leadership Institute. “And with health reform, the program will expand even more, to serve as many as one quarter of all Americans. “As such, the biggest challenge facing directors is to maximize opportunities to expand access, improve quality and control costs, particularly for the program’s highest-need and highest-cost patient subsets.”
Medicaid directors competitively selected to participate in the executive leadership development program are:
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
New PTSD Treatment Shows Promise with Brexpiprazole, Sertraline Combination
December 24th 2024Currently, the only medications approved by the FDA for PTSD are the selective serotonin reuptake inhibitors (SSRIs) sertraline and paroxetine. However, these medications don’t work for everyone.
Read More